Christopher Flint Obrien Sells 52,817 Shares of Neurocrine Biosciences, Inc. (NBIX) Stock
Neurocrine Biosciences, Inc. (NASDAQ:NBIX) insider Christopher Flint Obrien sold 52,817 shares of the business’s stock in a transaction on Tuesday, September 5th. The stock was sold at an average price of $57.50, for a total value of $3,036,977.50. Following the completion of the sale, the insider now directly owns 101,790 shares in the company, valued at $5,852,925. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.
Christopher Flint Obrien also recently made the following trade(s):
- On Thursday, July 27th, Christopher Flint Obrien sold 8,734 shares of Neurocrine Biosciences stock. The stock was sold at an average price of $50.00, for a total value of $436,700.00.
Shares of Neurocrine Biosciences, Inc. (NASDAQ NBIX) traded down 1.55% on Thursday, hitting $57.73. The stock had a trading volume of 874,370 shares. The company’s market cap is $5.09 billion. Neurocrine Biosciences, Inc. has a 12 month low of $37.35 and a 12 month high of $60.00. The company’s 50 day moving average price is $52.12 and its 200-day moving average price is $48.30.
Neurocrine Biosciences (NASDAQ:NBIX) last posted its quarterly earnings data on Thursday, August 3rd. The company reported ($0.68) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.67) by $0.01. The firm had revenue of $6.34 million during the quarter, compared to analysts’ expectations of $0.61 million. During the same period last year, the firm earned ($0.46) earnings per share. On average, analysts expect that Neurocrine Biosciences, Inc. will post ($2.45) earnings per share for the current year.
NBIX has been the topic of several analyst reports. BidaskClub raised Neurocrine Biosciences from a “sell” rating to a “hold” rating in a report on Wednesday, June 21st. Leerink Swann dropped their target price on Neurocrine Biosciences from $68.00 to $66.00 and set an “outperform” rating on the stock in a report on Thursday, May 25th. Bank of America Corporation reissued a “buy” rating and issued a $70.00 target price on shares of Neurocrine Biosciences in a report on Monday, May 15th. Oppenheimer Holdings, Inc. reissued an “outperform” rating and issued a $70.00 target price on shares of Neurocrine Biosciences in a report on Wednesday, July 5th. Finally, BMO Capital Markets reissued an “outperform” rating and issued a $75.00 target price on shares of Neurocrine Biosciences in a report on Thursday, May 25th. Two equities research analysts have rated the stock with a hold rating and seventeen have assigned a buy rating to the company’s stock. Neurocrine Biosciences presently has an average rating of “Buy” and a consensus price target of $68.25.
Several institutional investors have recently bought and sold shares of NBIX. Teachers Advisors LLC boosted its position in shares of Neurocrine Biosciences by 6.3% in the 4th quarter. Teachers Advisors LLC now owns 78,287 shares of the company’s stock worth $3,030,000 after purchasing an additional 4,668 shares in the last quarter. Capstone Asset Management Co. acquired a new stake in shares of Neurocrine Biosciences in the 1st quarter worth $214,000. Nationwide Fund Advisors boosted its position in shares of Neurocrine Biosciences by 20.9% in the 1st quarter. Nationwide Fund Advisors now owns 126,631 shares of the company’s stock worth $5,483,000 after purchasing an additional 21,922 shares in the last quarter. First Mercantile Trust Co. boosted its position in shares of Neurocrine Biosciences by 22.2% in the 1st quarter. First Mercantile Trust Co. now owns 3,082 shares of the company’s stock worth $133,000 after purchasing an additional 560 shares in the last quarter. Finally, Wells Fargo & Company MN boosted its position in shares of Neurocrine Biosciences by 143.9% in the 1st quarter. Wells Fargo & Company MN now owns 297,122 shares of the company’s stock worth $12,864,000 after purchasing an additional 175,292 shares in the last quarter.
About Neurocrine Biosciences
Neurocrine Biosciences, Inc is engaged in discovering and developing pharmaceuticals, in diseases with unmet medical needs, through its research and development (R&D) platform, focused on neurological and endocrine based diseases and disorders. Its three lead late-stage clinical programs are elagolix, which is a gonadotropin-releasing hormone (GnRH) antagonist for endometriosis and uterine fibroids; INGREZZA (valbenazine), which is a vesicular monoamine transporter 2 (VMAT2) inhibitor, for the treatment of movement disorders, and opicapone, which is a selective catechol-O-methyltransferase inhibitor that is an adjunct therapy to preparations of levodopa/Dihydroxyphenylalanine (DOPA) decarboxylase inhibitors for adult patients with Parkinson’s disease.
Receive News & Ratings for Neurocrine Biosciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neurocrine Biosciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.